Articles

Doctors, pharmacists, and even drug company sales reps are all paid based on performance because it incentivizes desired outcomes.

Applications are now closed.

Paul Ginsburg discusses how for decades, stakeholders have argued about whether competition or regulation should be the approach to constrain health care spending. By having chosen neither, he argues, our nation now finds itself with a much larger challenge. The magnitude of our health care affordability problem cries out for pursuing both competition and regulation.

As a cancer researcher and a health economist, we’ve seen up close through our lab and consulting work the revolution contained in a blood draw. But cancer detection blood tests aren’t built into annual physicals like standard blood tests, and so far they aren’t covered by insurance.

Health Affairs Editor-in-Chief Alan Weil interviews Jack Chapel, a PhD candidate in economics at the USC Dornsife College of Letters, Arts and Sciences, about a new study examining the worsening health and economic trends for Americans with modest resources nearing retirement.

Researchers study the health and economics issues associated with cognitive decline and dementia, and particularly the inequitable burden of Alzheimer’s.

Schaeffer experts submitted a comment letter responding to a recent request for information (RFI) regarding medical payment products.

A new study from the USC Schaeffer Center and Harvard University is the first to examine the “revolving door” in health care.

Since 2012, the Schaeffer Center has received $6.1 million in funding from the NIH to fund pilot projects by junior scholars focused on addressing disparities. This year we are seeking junior scientists concentrating on Alzheimer’s disease and related dementias in minority populations.

Medicare released the list of the first 10 drugs subject to price negotiations under the Inflation Reduction Act (IRA), aiming to reduce drug costs for Medicare enrollees and taxpayers.